May 30, 2024, Gan & Lee Pharmaceuticals announced will be attending the BIO International Convention in San Diego, California, USA, June 3-6, 2024 (PST), and will give company presentation on June 5, 2024, at 3:45 p.m. (PST).The team will share the latest R&D progress of GZR18 (potential biweekly GLP-1 RA), GZR4 (weekly insulin analogue), GZR101 (dual insulin analogue) and other projects developed based on the proprietary intellectual property technology platform, demonstrate Gan & Lee's technological strength and innovation in the field of endocrine by focusing on the company's R&D strategies and international business layout. Meanwhile, the team will communicate with global famous pharmaceutical and investment organizations through the One-of-One online appointment system.

Founded in 1993, BIO is the world's largest and most comprehensive biotechnology event, representing the complete ecosystem of biotechnology. This year's convention is themed "Time for Science to Shine"and will gather industry-leading biopharmaceutical companies, investors and collaborators from all over the world, and a number of collaborative activities will be held during the conference, aiming to promote the development of biotechnology and pharmaceutical industries and international exchanges and cooperation.

Corporate Presentation Information

Time: June 5, 2024 at 15:45 (PST) (BST: June 6 at 06:45)

Location：Company Presentation Theater 2

Theme: Gan & Lee Pharmaceutical's latest R&D progress on innovative drug programs

Contact：BD@ganlee.com

Convention Information

Name：BIO International Convention 2024

Time：June 3-6, 2024 (PST)

Website：https://convention.bio.org/, for more detailed information

Location：San Diego Convention Center, San Diego, CA

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.